Spouses of individuals living with mild cognitive impairment or dementia in the United States: A descriptive, population-based study.

BACKGROUND: Little is known about the population of individuals who live with a spouse with cognitive impairment (CI) or dementia. METHODS: Using the US Health and Retirement Study, 2000 to 2018, we estimated the population of adults ≥ 50 years old co-residing with a spouse with probable CI/dementia. We described their socio-demographic and health characteristics and quantified socio-demographic inequities. RESULTS: Among community-dwelling adults ≥ 50 years old, 6% of women and 4% of men co-resided with a spouse with probable CI/dementia. Among those who were married/partnered, the prevalence of spousal dementia was greater for Black and Hispanic adults compared to their White counterparts, and for those with lower versus higher educational attainment. Among spouses, activities of daily living disability, depression, and past 2-year hospitalization was common. DISCUSSION: Millions of older adults, disproportionately Black and Hispanic people and people with lower levels of educational attainment, live with a spouse with CI while also facing their own major health challenges.

Association Between Assistance With Medicaid Enrollment and Use of Health Care After Incarceration Among Adults With a History of Substance Use.

Importance: The transition from prison to community is characterized by elevated morbidity and mortality, particularly owing to drug overdose. However, most formerly incarcerated adults with substance use disorders do not use any health care, including treatment for substance use disorders, during the initial months after incarceration. Objective: To evaluate whether a prerelease Medicaid enrollment assistance program is associated with increased health care use within 30 days after release from prison. Design, Setting, and Participants: This retrospective cohort study included 16 307 adults aged 19 to 64 years with a history of substance use who were released from state prison between April 1, 2014, and December 31, 2016. The Wisconsin Department of Corrections implemented prerelease Medicaid enrollment assistance in January 2015. Statistical analysis was performed from January 1 to August 31, 2021. Exposure: A statewide Medicaid prerelease enrollment assistance program. Main Outcomes and Measures: The main outcome was Medicaid-reimbursed health care, associated with substance use disorders and for any cause, within 30 days of prison release, including outpatient, emergency department, and inpatient care. Mean outcomes were compared for those released before and after implementation of prerelease Medicaid enrollment assistance using an intention-to-treat analysis and person-level data from the Wisconsin Department of Corrections and Medicaid. Results: The sample included 16 307 individuals with 18 265 eligible releases (men accounted for 16 320 of 18 265 total releases, and 6213 of 18 265 releases were among Black individuals; mean [SD] age at release, 35.5 [10.7] years). The likelihood of outpatient care use within 30 days of release increased after implementation of enrollment assistance relative to baseline by 7.7 percentage points for any visit (95% CI, 6.4-8.9 percentage points; P < .001), by 0.7 percentage points for an opioid use disorder visit (95% CI, 0.4-1.0 percentage points; P < .001), by 1.0 percentage point for any substance use disorder visit (95% CI, 0.5-1.6 percentage points; P < .001), and by 0.4 percentage points for receipt of medication for opioid use disorder (95% CI, 0.2-0.6 percentage points; P < .001). There was no significant change in use of the emergency department (0.7 percentage points [95% CI, -0.15 to 1.4 percentage points]). The probability of an inpatient stay increased by 0.4 percentage points (95% CI, 0.03-0.7 percentage points; P = .03). Conclusions and Relevance: The results of this cohort study suggest that prerelease Medicaid enrollment assistance was associated with increased use of outpatient health care after incarceration and highlights the value of making this assistance universally available within correctional settings. More tailored interventions may be needed to increase the receipt of treatment for substance use disorders.

Steady-state operation of a biofilter coupled with photocatalytic control of bacterial bioaerosol emissions.

Bioaerosols are emitted during the biological treatment of water, soil, and air pollutants. The elimination of these pollutants has become a priority due to their detrimental effects on human health. Advanced oxidation technologies have been used to control bioaerosol emissions specially to improve indoor air quality. This investigation was focused on evaluating the biofiltration of ethyl acetate vapors in terms of removal efficiency and bioaerosol emission. Also, a continuous photocatalytic process to inactivate bioaerosols emitted from the biofilter was assessed as a post-treatment. The photocatalysis was developed with ZnO and TiO2 immobilized onto Poraver glass beads. Flow cytometry (FC) coupled with fluorochromes was used to characterize and quantify bioaerosol emissions in terms of live, dead, and injured cells. Ethyl acetate removal efficiencies were maintained in a steady state with values of 100% under 60-g m-3 h-1 inlet load (IL). Biomass concentration in the biofilter reached values up to 228 mgbiomass gperlite-1 at day 56 of operation, but the spontaneous occurrence of predatory mites diminished biomass concentration by 33%. Bioaerosols emitted during the steady-state operation of the biofilter were composed mainly by bacteria (~ 94%) and in a less extent of fungal spores (0.29-6%). The most efficient photocatalytic system comprised TiO2/Poraver with 78% inactivation of bioaerosols during the first 2 h of the process, whereas the ZnO/Poraver system showed null activity (~ 0%) of inactivation. FC results show that the main mechanism of inactivation of TiO2/Poraver was cell death.

Asociación entre las tasas de homicidio y de suicidio en Colombia, 2017 / Association between homicide and suicide rates in Colombia, 2017

El contexto socioeconómico guarda relación significativa con las tasas de homicidio y de suicidio1. Por un lado, se plantea que las condiciones socioeconómicas adversas incrementan las tasas de homicidio y de suicidio en una población por el incremento de los comportamientos agresivos y violentos tanto hacia otros como contra sí mismos2. Y por el otro, se considera que el malestar socioeconómico solo incrementa los homicidios, con reducción o mantenimiento de la tasa de suicidio, lo que resulta en aumento de la proporción entre homicidios y suicidios, es decir, en países con situación socioeconómica favorable, se reducen los homicidios y se elevan los casos de suicidios porque, si no se encuentra una causa externa al malestar, como desempleo o pobreza, la violencia hacia a uno mismo se multiplica3. De la misma manera, se postula que las situaciones de conflictos armados, o guerras propiamente dichas, afectan a la tasa de suicidios; las muertes por suicidio se reducen significativamente y las muertes por la guerra se multiplican de modo exponencial.

The socio-economic context is significantly related to homicide and suicide rates1 . On the one hand, it is argued that adverse socio-economic conditions increase homicide and suicide rates in a population by increasing aggressive and violent behaviour both towards others and towards oneself2. On the other hand, it is considered that socio-economic distress only increases homicides, with a reduction or maintenance of the suicide rate, which results in an increase in the ratio between homicides and suicides, i.e. in countries with a favourable socio-economic situation, homicides are reduced and cases of suicide increase because, if no external cause of the distress is found, such as unemployment or poverty, violence towards oneself multiplies3. In the same way, it is postulated that situations of armed conflict, or wars per se, affect the suicide rate; suicide deaths are significantly reduced and war deaths multiply exponentially4.

A Double-Blind, Active-Controlled Clinical Trial of Sodium Bicarbonate and Calcium Gluconate in the Treatment of Bilateral Osteoarthritis of the Knee.

OBJECTIVE: To evaluate the effect of intra-articular injections of sodium bicarbonate with a single (SBCG1) or double dose (SBCG2) of calcium gluconate administered monthly compared with methylprednisolone (MP) for treatment of knee osteoarthritis. METHODS: A 3-month, randomized, double-blind clinical trial with patients diagnosed with knee osteoarthritis (OA). The outcome variables were the Western Ontario-McMaster University Osteoarthritis Index (WOMAC) and the Lequesne functional index. RESULTS: After 3 months, all treatments significantly improved in overall WOMAC and Lequesne scores. Mean changes (95% confidence interval) in WOMAC total score and the Lequesne index, respectively, for SBCG1 (-12.5 [-14.3, -10.7]; -9.0 [-11.4, -6.7]) and SBCG2 (-12.3 [-14.3, -10.4]; -8.9 [-10.4, -7.4]) were significantly greater than for MP (-5.0 [-7.2, -2.8]; -3.2 [-4.9, -1.5]) (P < .001). CONCLUSIONS: Intra-articular injections of sodium bicarbonate and calcium gluconate are useful for short-term relief of OA symptoms in patients with bilateral knee osteoarthritis. Both treatments are more effective than MP injections in the reduction of knee OA symptoms. TRIAL REGISTRATION: Clinicaltrials.gov NCT00977444.

Effectiveness of intra-articular injections of sodium bicarbonate and calcium gluconate in the treatment of osteoarthritis of the knee: a randomized double-blind clinical trial.

BACKGROUND: A novel therapeutic management of osteoarthritis (OA) of the knee was assessed. The study aimed to evaluate the effect of monthly sodium bicarbonate with a single (SBCG1) or double dose (SBCG2) of calcium gluconate injections on OA of the knee; as well as the efficacy and safety of both SBCG interventions in the long term. METHODS: A double-blind parallel-group clinical trial with 74 knee OA patients was performed during 12 months, both SBCG interventions were followed-up for another 6mo after intervention. The outcome variables were the Western Ontario-McMaster University Osteoarthritis Index (WOMAC), the Lequesne's functional index and joint-space width changes from serial radiographs. RESULTS: After 12 months, group SBCG1 decreased -14.8 (95% CI:-14.2, -17.0) and group SBCG2 decreased -14.6 (-16.9, -12.4) in the global WOMAC score, the mean changes represent 80% and 82% lessened pain, respectively. In the Lequesne Functional Index scale, SBCG1 decreased -11.9 (-10.4, -14.2) and SBCG2 decreased -11.9 (-13.8, -10.0), representing 66 and 69% of improvement. Both mean scores were maintained after intervention discontinued. SBCG2 improved the knees' joint space width more than SBCG1 at 3 and 18 months. Both SBCG interventions were well tolerated after 12 months of treatment CONCLUSION: A solution of sodium bicarbonate and calcium gluconate is effective on reducing the symptoms associated with OA. Its beneficial effect is maintained for one year of continuous monthly administration and at least for 6 months after the administration is discontinued. When the dose of calcium gluconate is increased, it prevents further narrowing of joint-space. TRIAL REGISTRATION: Clinicaltrials.gov NCT00977444 September 11, 2009.

Leishmaniosis ¿cuándo hospitalizar? / Leishmaniosis ¿When to Hospitalize?

La leishmaniosis es una enfermedad infecciosa parasitaria, endémica, de distribución mundial, que en Venezuela se presenta como leishmaniosis tegumentaria americana (cutánea localizada, cutáneomucosa y cutáneo difusa) además de la forma visceral (kala azar). La variedad cutánea localizada representa el 90 por ciento de los casos atendidos en la consulta de Endemias Rurales del Instituto de Medicina Tropical y en los Servicios de Pediatría Médica y Enfermedades Infecciosas del Adulto del Hospital Universitario de Caracas, y la mayoría son tratados ambulatoriamente con antimoniato de meglumina. En algunas situaciones clínicas es necesaria la hospitalización. Se describen ocho casos hospitalizados: 1) niña de dos años con leishmaniosis cutánea que había recibido inmunoterapia para la parasitosis; 2) paciente de 59 años con leishmaniosis de la mucosa nasal; 3) paciente de 64 años con úlcera de los chicleros en el pabellón auricular; 4) paciente de 36 años con falla terapéutica a la meglumina, quien había recibido inmunoterapia para leishmaniosis; 5) paciente de 59 años alcohólico, con ulceración extensa de cinco años de evolución; 6) mujer de 83 años con leishmaniosis cutánea en miembros inferiores; 7) paciente con leishmaniosis de la mucosa nasal y SIDA; 8) paciente de 37 años con kala azar. Se analizan las razones para la hospitalización y las dosis de antimoniato de meglumina empleadas para la solución terapéutica

Leishmaniasis is an endemic parasitic infectious disease of worldwide distribution. In Venezuela the main characteristics correspond to american tegumentary leishmaniasis (cutaneous localized, cutaneous-mucous, cutaneous diffuse) and visceral leishmaniasis (kala azar). The localized cutaneous variety represents 90 percent of the cases attended at the ambulatory medical clinic for rural endemic diseases at the Tropical Medicine Institute, Pediatric and Adult services for Infectious Diseases at the Universitary Hospital of Caracas, and these patients are treated with pentavalent antimonials. In some clinical conditions hospitalization is required. We describe eight cases of patients treated under hospitalization. Case 1) a two year old girl with cutaneous leishmaniasis who had received immunotherapy for this parasitic disease; case 2) fifty nine year old female with nasal leishmaniasis; case 3) sixty four year old male with a rubber tapper’s ulcer in the ear; case 4) thirty six year old male with treatment failure to pentavalent antimonials having received immunotherapy for leishmaniasis; case 5) fifty nine year old male alcoholic patient, with extended ulcer of five years evolution; case 6) eighty three year old female with cutaneous leishmanisis in the legs; case 7) thirty three year old male with leishmaniasis of the nasal mucosa and AIDS; case 8) thirty seven year old male with kala azar. We discuss the reasons for hospitalization and the dosage of pentavalent antimonials administered

Severe stunned myocardium after lightning strike.

OBJECTIVE: To report the development of myocardial stunning and severe heart failure after lightning strike with total recovery of function. DESIGN: Case report. SETTING: Coronary care unit at Medica Sur Clinic, Mexico. PATIENT: A 42-yr-old woman who was hit by lightning developed rapid and progressive hemodynamic deterioration manifested by cardiogenic shock that required invasive monitoring. Twenty-four hours after the strike, intravenous levosimendan and intra-aortic balloon pump were initiated because the patient demonstrated no significant response to management with conventional inotropic agents. Two days later, echocardiographic signs of systolic and diastolic dysfunction improved markedly. Dual-isotope-imaging myocardial perfusion testing with technetium-99m-sestamibi and thallium-201, performed 9 days after admission, showed normal perfusion and normal left ventricular systolic function. The patient exhibited complete recovery of function. The exact mechanism of abnormal contractility in the absence of direct electrofulguration is unknown but may be explained by release of oxygen free radicals, proteolysis of the contractile apparatus, and cytosolic overload of intracellular calcium, followed by reduced myofilament sensitivity to calcium. These abnormalities are consistent with stunned myocardium. CONCLUSIONS: Lightning strike may cause serious contractile dysfunction in the absence of irreversible myocardial injury, but the exact mechanism of this phenomenon remains unknown. We propose that lighting strike can cause myocardial stunning resulting in severe but reversible left ventricular dysfunction. The patient's recovery was facilitated by support treatment including administration of levosimendan, which increases the intracellular sensitivity to calcium, a mechanism disturbed in patients with myocardial stunning.